ArticleAnnals of medicine2024

Stable or at least once HER2-low status during neoadjuvant chemotherapy confers survival benefit in patients with breast cancer.

Yingying Zhao et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.